# Emergent BioSolutions

Emergent BioSolutions is an other based in Gaithersburg, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Gaithersburg, United States
- **Region:** North America
- **Address:** 300 Professional Drive, Suite 400, Gaithersburg, MD 20879, United States
- **Assets under management:** Undisclosed
- **Website:** emergentbiosolutions.com

## Regulatory record

- **Reports private funds:** No

## About

Emergent BioSolutions operates as a specialty life sciences company focused on public health threats, both intentional and naturally emerging. It was founded in 1998 but the website does not list founders; the firm went public in 2006. Its core business is developing and manufacturing medical countermeasures for biodefense, alongside commercial products addressing the opioid epidemic. Strategy and deployment center on three segments: commercial products (including NARCAN Nasal Spray for opioid overdose), medical countermeasures (anthrax, smallpox, botulism, Ebola treatments), and strategic partnerships with biopharma innovators and governments. The firm operates facilities across the US, Canada, Ireland, UK, and Singapore. Confirmed products include BioThrax, ACAM2000, BAT, and Ebanga. Revenues are heavily tied to US government procurement through the Strategic National Stockpile. As a public company, Emergent BioSolutions Inc. traded on the NYSE (ticker EBS). The firm reported approximately $1 billion in annual revenue in fiscal 2023, though recent financial disclosures show operational losses and restructuring. In February 2025, the firm received a $64.5 million contract modification for BAT botulism antitoxin to support US biodefense strategy (per company news, February 2025). The structural differentiator is Emergent's near-total dependence on a single customer — the US government — via the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense. This creates extreme regulatory and political concentration risk.

## Sectors

- Healthcare Services
- Biotech
- Public Health
- National Security

## Offices

- Washington, DC, United States
- Canton, MA, United States
- Lansing, MI, United States
- Plymouth Meeting, PA, United States
- Mississauga, Ontario, Canada
- Winnipeg, Manitoba, Canada
- Dublin, Ireland
- London, England, United Kingdom
- Singapore
- Germany

## Questions

### What is Emergent BioSolutions' primary revenue source?

The majority of revenue comes from US government contracts, primarily through the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, for medical countermeasures such as anthrax and smallpox vaccines (per company filings).

### Does Emergent BioSolutions only sell to the US government?

No. It also commercializes products like NARCAN Nasal Spray for opioid overdose and has international approvals, such as Saudi FDA approval for ACAM2000 smallpox vaccine (per company news). The firm operates partnerships with biopharma innovators globally.

### What are Emergent BioSolutions' key product categories?

Key categories are medical countermeasures (anthrax vaccine BioThrax, smallpox vaccine ACAM2000, botulism antitoxin BAT, Ebola treatment Ebanga) and commercial products (NARCAN Nasal Spray for opioid overdose). The firm also provides contract development and manufacturing services.

### Has Emergent BioSolutions faced any operational challenges?

Yes. The firm has disclosed operational losses and restructuring in recent financial filings, including a $64.5 million contract modification in February 2025 for BAT botulism antitoxin. Its heavy reliance on US government contracts creates concentration risk.

### Where are Emergent BioSolutions' manufacturing and R&D sites located?

Manufacturing operations are in Lansing, MI; Canton, MA; and Winnipeg, Canada. Science and development sites are in Gaithersburg, MD; Winnipeg; and Dublin, Ireland. Sales offices span the US, Canada, UK, and Germany.

### Is Emergent BioSolutions a public or private company?

Emergent BioSolutions Inc. is a publicly traded company on the NYSE under the ticker EBS. It went public in 2006.

### Does Emergent BioSolutions only develop vaccines?

No. It develops and manufactures a range of medical countermeasures including vaccines, antitoxins (BAT for botulism), immune globulins (ANTHRASIL, CNJ-016), and antiviral therapies (TEMBEXA for smallpox), plus commercial products for opioid overdose.

## Related profiles

- [Lydall](https://altss.com/profile/lydall)
- [Ontario Power Generation Inc.](https://altss.com/profile/ontario-power-generation-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/emergent-biosolutions-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology